Showing 161-170 of 190 results for "".
Management of Female Pattern Hair Loss
https://practicaldermatology.com/topics/hair-nails/management-of-female-pattern-hair-loss/22975/Creating and maintaining healthy, normal hair growth and scalp skin is a daily activity that requires a lifestyle change to maintain the benefits of a good hair care program.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-44/23875/Is Biopsy Effective for BCC on the Head and Neck?; Ask an Expert: Wound Care and Healing
https://practicaldermatology.com/youngmd-connect/resident-resource-center/is-biopsy-effective-for-bcc-on-the-head-and-neck-ask-an-expert-wound-care-and-healing/21141/Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/20614/Indoor Tanning Beds: The Dangers of Adolescent Tanning
https://practicaldermatology.com/topics/skin-cancer-photoprotection/indoor-tanning-beds-the-dangers-of-adolescent-tanning/22973/As research continues to shed light on the connection between UV exposure and skin cancer, greater efforts are required to inform the public and affect the legislative process.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments/21709/Therapeutics Update: Notable Approvals in 2017
https://practicaldermatology.com/topics/skin-cancer-photoprotection/therapeutics-update-notable-approvals-in-2017/20398/A look at the newest additions to the medicine chest.Recent Developments
https://practicaldermatology.com/columns/recent-developments/recent-developments-38/23774/2019 In Review
https://practicaldermatology.com/topics/practice-management/2019-in-review/23168/A look back at approvals, data, and industry developments of the year.- ACLARIS files NDA For Novel Seborrheic Keratosis Treatmenthttps://practicaldermatology.com/news/aclaris-files-nda-for-novel-seborrheic-keratosis-treatment/2458272/Aclaris Therapeutics, Inc. submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for A-101 40% topical solution (A-101) as a treatment for seborrheic keratosis (SK). If approved, A-101 would be the first FDA-approved t